Evercore ISI Group Maintains Outperform on TG Therapeutics, Lowers Price Target to $71
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Michael DiFiore maintains TG Therapeutics (NASDAQ:TGTX) with a Outperform and lowers the price target from $73 to $71.
Evercore ISI Group analyst Michael DiFiore maintains TG Therapeutics (NASDAQ:TGTX) with a Outperform and lowers the price target from $73 to $71.